Matching articles for "sleep disorders"
Issue 1579 · August 26, 2019
Solriamfetol (Sunosi) for Excessive Daytime Sleepiness

The FDA has approved solriamfetol ( Sunosi – Jazz), a dopamine and norepinephrine reuptake inhibitor (DNRI), to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with…

Med Lett Drugs Ther. 2019 Aug 26; 61(1579):132-4
The FDA has approved solriamfetol ( Sunosi – Jazz), a dopamine and norepinephrine reuptake inhibitor (DNRI), to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA). Pitolisant (Wakix) , an H3-receptor antagonist/inverse agonist recently approved by the FDA for treatment of excessive daytime sleepiness in patients with narcolepsy, will be reviewed in a future issue.
Issue 1444 · June 9, 2014 Free
In Brief: Lowering the Dose of Lunesta

The FDA has required the manufacturer of eszopiclone ( Lunesta – Sunovion), a benzodiazepine receptor agonist approved for the treatment of insomnia, to lower the current recommended starting dose to 1 mg…

Med Lett Drugs Ther. 2014 Jun 9; 56(1444):48
The FDA has required the manufacturer of eszopiclone ( Lunesta – Sunovion), a benzodiazepine receptor agonist approved for the treatment of insomnia, to lower the current recommended starting dose to 1 mg for both men and women because a new study found that an evening dose of 3 mg can impair driving skills, memory, and coordination for more than 11 hours. 1 Eszopiclone’s half-life is longer than that of any other drug in its class, which includes zolpidem ( Ambien , and generics) and zaleplon ( Sonata , and generics). All benzodiazepine receptor agonists may impair performance the next morning, including driving. 2 Anterograde amnesia and complex sleep-related behaviors without conscious awareness may also occur. Hallucinations have been reported. Like the benzodiazepines, benzodiazepine receptor agonists are schedule IV controlled substances; withdrawal, dependence, and abuse can occur. 1. FDA Drug Safety Communication. FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose. Available at www.fda.gov. Accessed May 29, 2014. 2. Drugs for insomnia. Treat Guidel Med Lett 2012; 10:57. Download complete U.S. English article
Issue 1441 · April 28, 2014
Tasimelteon (Hetlioz) for Non-24-Hour Sleep-Wake Disorder

The FDA has approved the melatonin receptor agonist tasimelteon ( Hetlioz – Vanda) for treatment of non-24-hour sleep-wake disorder (non-24), which is common in totally blind persons. Tasimelteon is the…

Med Lett Drugs Ther. 2014 Apr 28; 56(1441):34-5
The FDA has approved the melatonin receptor agonist tasimelteon ( Hetlioz – Vanda) for treatment of non-24-hour sleep-wake disorder (non-24), which is common in totally blind persons. Tasimelteon is the first drug approved for this indication and the second melatonin receptor agonist approved for use in the US; ramelteon (Rozerem) was approved earlier for treatment of insomnia. Melatonin itself has not been approved by the FDA for any indication; it is available in the US as a dietary supplement and is promoted as a sleep aid.
Issue 1408 · January 21, 2013
FDA Requires Lower Dosing of Zolpidem

On January 10, 2013, the FDA issued a news release to announce that it was requiring the manufacturers of the zolpidem-containing products Ambien , Ambien CR , Edluar and Zolpimist , which are all approved for…

Med Lett Drugs Ther. 2013 Jan 21; 55(1408):5
On January 10, 2013, the FDA issued a news release to announce that it was requiring the manufacturers of the zolpidem-containing products Ambien , Ambien CR , Edluar and Zolpimist , which are all approved for treatment of insomnia, to lower the doses for women and to recommend in their labeling consideration of a lower dose for men. No change will be required in the dose of Intermezzo , a low-dose sublingual formulation of zolpidem for middle-of-the-night awakening, which is already recommended in a lower dose for women.
Issue 1384 · February 20, 2012
Zolpidem Oral Spray (Zolpimist) for Insomnia

Zolpidem oral spray ( Zolpimist – NovaDel/ECR), a new formulation of the oral hypnotic zolpidem tartrate ( Ambien , and others), has been approved by the FDA for short-term treatment of insomnia…

Med Lett Drugs Ther. 2012 Feb 20; 54(1384):14-5
Zolpidem oral spray ( Zolpimist – NovaDel/ECR), a new formulation of the oral hypnotic zolpidem tartrate ( Ambien , and others), has been approved by the FDA for short-term treatment of insomnia characterized by difficulty falling asleep.
Issue 1348 · October 4, 2010
Low-Dose Doxepin (Silenor) for Insomnia

The FDA has approved a new low-dose formulation of the tricyclic antidepressant doxepin ( Silenor – Somaxon) for treatment of insomnia associated with sleep maintenance. The manufacturer claims that this…

Med Lett Drugs Ther. 2010 Oct 4; 52(1348):79-80
The FDA has approved a new low-dose formulation of the tricyclic antidepressant doxepin ( Silenor – Somaxon) for treatment of insomnia associated with sleep maintenance. The manufacturer claims that this dose retains the hypnotic effect of doxepin, without typical tricyclic adverse effects. Doxepin is available generically in higher-strength capsules and in a liquid formulation.
Issue 1344 · August 9, 2010
Armodafinil (Nuvigil) for Wakefulness

Armodafinil ( Nuvigil – Cephalon), the R-enantiomer of the non-amphetamine stimulant modafinil ( Provigil – Cephalon; Alertec – Shire in Canada), is being promoted directly to the public for treatment of…

Med Lett Drugs Ther. 2010 Aug 9; 52(1344):61-2
Armodafinil ( Nuvigil – Cephalon), the R-enantiomer of the non-amphetamine stimulant modafinil ( Provigil – Cephalon; Alertec – Shire in Canada), is being promoted directly to the public for treatment of excessive daytime sleepiness associated with shift work.
Issue 1336 · April 19, 2010
Edluar - A New Sublingual Formulation of Zolpidem

Edluar (Meda), a new sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem ( Ambien , and others), has been approved by the FDA for treatment of insomnia.

Med Lett Drugs Ther. 2010 Apr 19; 52(1336):29-30
Edluar (Meda), a new sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem ( Ambien , and others), has been approved by the FDA for treatment of insomnia.
Issue 79 · March 1, 2009
Drugs for Insomnia

The majority of patients with insomnia do not have a predisposing psychiatric disease. Rather, untreated insomnia may be a risk factor for development of psychiatric problems such as depression or anxiety.

Treat Guidel Med Lett. 2009 Mar; 7(79):23-6
The majority of patients with insomnia do not have a predisposing psychiatric disease. Rather, untreated insomnia may be a risk factor for development of psychiatric problems such as depression or anxiety.
Issue 62 · October 1, 2007
Drugs for Parkinson's Disease

ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the…

Treat Guidel Med Lett. 2007 Oct; 5(62):89-94
ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the bloodbrain barrier.
Issue 42 · February 1, 2006
Drugs for Insomnia

Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective and durable than…

Treat Guidel Med Lett. 2006 Feb; 4(42):5-10
Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective and durable than treatment with drugs. Hypnotic drugs are generally FDA-approved only for short-term use, but in practice they often are taken much longer.
Issue 1227 · January 30, 2006
A New Indication for Gamma Hydroxybutyrate (Xyrem) in Narcolepsy

Gamma hydroxybutyrate (GHB), a central-nervous-system depressant notorious for its use in "date rape", was approved by the FDA in 2002 as sodium oxybate ( Xyrem - Jazz Pharmaceuticals) for oral treatment of…

Med Lett Drugs Ther. 2006 Jan 30; 48(1227):11-2
Gamma hydroxybutyrate (GHB), a central-nervous-system depressant notorious for its use in "date rape", was approved by the FDA in 2002 as sodium oxybate ( Xyrem - Jazz Pharmaceuticals) for oral treatment of cataplexy in patients with narcolepsy. Now it has also been approved for treatment of excessive daytime sleepiness (EDS) in these patients. Xyrem is a Schedule III controlled substance.
Issue 1223 · December 5, 2005
Ambien CR for Insomnia

Zolpidem ( Ambien - Sanofi-Aventis), a nonbenzodiazepine benzodiazepine receptor agonist, is the most frequently prescribed hypnotic in the US. As its patent approaches expiration, its manufacturer has…

Med Lett Drugs Ther. 2005 Dec 5; 47(1223):97-8
Zolpidem ( Ambien - Sanofi-Aventis), a nonbenzodiazepine benzodiazepine receptor agonist, is the most frequently prescribed hypnotic in the US. As its patent approaches expiration, its manufacturer has received FDA approval to market an extended-release formulation of the drug, Ambien CR . The pharmacological rationale for doing so is that short-acting hypnotics like zolpidem are more effective at inducing sleep than they are at maintaining it.
Issue 1203 · February 28, 2005
Eszopiclone (Lunesta), a New Hypnotic

Eszopiclone ( Lunesta - Sepracor), a benzodiazepine-like drug, has been approved by the FDA for oral treatment of insomnia. It is the S-isomer of zopiclone ( Imovane , and others in Canada), which has been…

Med Lett Drugs Ther. 2005 Feb 28; 47(1203):17-9
Eszopiclone ( Lunesta - Sepracor), a benzodiazepine-like drug, has been approved by the FDA for oral treatment of insomnia. It is the S-isomer of zopiclone ( Imovane , and others in Canada), which has been available in other countries for almost 20 years. Unlike similar drugs such as zolpidem ( Ambien ) or zaleplon ( Sonata ), Lunesta is not being restricted in its labeling to short-term use. Like other hypnotics, eszopiclone is a schedule IV drug.
Issue 22 · June 1, 2004
Drugs for Parkinson's Disease

Parkinson's disease is caused by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat Parkinson's disease because it does not cross the…

Treat Guidel Med Lett. 2004 Jun; 2(22):41-6
Parkinson's disease is caused by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat Parkinson's disease because it does not cross the blood-brain barrier.
Issue 1181 · April 26, 2004
New Indications for Modafinil (Provigil)

Modafinil ( Provigil - Cephalon; Alertec - Draxis in Canada), first approved by the FDA in 1999 for treatment of excessive daytime sleepiness associated with narcolepsy ( Medical Letter 1999; 41:30 ), has now…

Med Lett Drugs Ther. 2004 Apr 26; 46(1181):34-5
Modafinil ( Provigil - Cephalon; Alertec - Draxis in Canada), first approved by the FDA in 1999 for treatment of excessive daytime sleepiness associated with narcolepsy ( Medical Letter 1999; 41:30 ), has now also been approved for treatment of patients with excessive sleepiness due to obstructive sleep apnea/hypopnea syndrome (OSAHS) or shift work sleep disorder (SWSD) (DSM-IV, text revision, Washington, DC: American Psychiatric Association, 2000, page 622).
Issue 1145 · December 9, 2002
Gamma Hydroxybutyrate (Xyrem) for Narcolepsy

The FDA has approved use of gamma hydroxybutyrate (sodium oxybate is the official generic name; Xyrem - Orphan Medical) for oral treatment of cataplexy in patients with narcolepsy. Gamma hydroxybutyrate (GHB),…

Med Lett Drugs Ther. 2002 Dec 9; 44(1145):103-5
The FDA has approved use of gamma hydroxybutyrate (sodium oxybate is the official generic name; Xyrem - Orphan Medical) for oral treatment of cataplexy in patients with narcolepsy. Gamma hydroxybutyrate (GHB), a metabolite of gamma-aminobutyric acid (GABA), is a central-nervous-system depressant marketed in Europe for use in general anesthesia. In recent years it has been notorious for its use in "date-rape" ( Medical Letter 2002; 44:21 ). Xyrem is a Schedule III controlled substance.